Finnadvance Secures €1.6 M EU Funding for Organ-on-Chip Development and Commercialization—Join Us for Fundraising to Revolutionize Drug R&D!
We are excited to share that Finnadvance has secured €1.6 M in funding from the European Union through 4 innovative projects, we are now looking for matching investor funding! Three independent committees of EU experts evaluated positively our business model and secured the investment. This marks a crucial step forward in our mission to bring our cutting-edge AKITA Organ-on-Chip technology to pharmaceutical research.
Strategic Use of Funding: The capital from the EU grant and matching investor fund will be pivotal for 1) scaling up the production of our innovative AKITA Organ-on-Chip platform to support growing sales, 2) supporting additional validation for enhancing market penetration, and 3) potentiating sales and marketing efforts. These platforms replicate human organ functions with ease of use and adaptability to standard laboratory workflows, and they offer a game-changing approach to drug discovery, disease modeling, and personalized medicine.
Why us and Why now? As we advance our prototypes and move toward commercialization, the next 1-2 years will be transformative. With AKITA, you have the opportunity to be part of a healthcare revolution that promises to:
- Reduce reliance on animal experimentation and de-risk preclinical drug testing by providing more accurate and humane alternatives.
- Accelerate drug discovery with faster tissue maturation, reducing time and costs.
- Higher predictability enables personalized medicine by the modeling of drug resistance processes in vitro
With this recent EU backing, we are well-positioned to scale our innovations and significantly impact drug R&D. Partner with Us and reach science@finnadvance.com
